NASDAQ · Biotechnology · USD
IRulya Therapeutics Inc. (IRLA) Stock Analysis
IRulya Therapeutics Inc. (IRLA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
IRLA Key Statistics
As of Oct 21, 2026Trading
- Open
- $39.99
- Previous Close
- $40.27
- Day's Range
- 34.01–40.98
- 52-Week Range
- 15.10–910.00
- Volume
- 215.23K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.33
Valuation
- Market Cap
- $35.27M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −214.01
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$83.98M
- Shares Outstanding
- 1.02M
- 1-Year Return
- −90.47%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 34.53K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, IRLA closed at $34.68, −90.47% over 1 year.
IRulya Therapeutics Inc. (IRLA) has a market capitalization of $35.27M.
In fiscal 2025, IRLA reported revenue of $0.00.
IRLA Stock Return by Calendar Year
IRulya Therapeutics Inc. (IRLA) return since May 2019: what $10,000 became
- 1 year
- $10,000 $953
- −90.47%
- 5 years
- $10,000 $30
- −99.70%
- Since May 2019
- $10,000 $53
- −99.47%
If you had invested $10,000 in IRulya Therapeutics Inc. (IRLA) at the close on May 9, 2019, the earliest close on record here, it would have been worth $53 at the close on October 21, 2026: −99.47% in total, −50.53% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −94.82% |
| 2025 | +79.14% |
| 2024 | +78.10% |
| 2023 | +64.84% |
| 2022 | −94.95% |
| 2021 | −54.57% |
| 2020 | −50.52% |
| 2019 (partial year) | +70.69% |
As of October 21, 2026.
IRLA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$83.98M | — |
| 2024 | $0.00 | −$56.83M | — |
| 2023 | $0.00 | −$31.39M | — |
| 2022 | $0.00 | −$51.66M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$50.43M | −$83.98M | — |
| 2024 | $0.00 | — | −$36.17M | −$56.83M | — |
| 2023 | $0.00 | — | −$27.14M | −$31.39M | — |
| 2022 | $0.00 | — | −$51.19M | −$51.66M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B